{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fu Q"],"funding":["Dengfeng project of Foshan First People’s Hospital","Natural Science Foundation of Guangdong Province","National Natural Science Foundation of China","Dengfeng project of Foshan First People's Hospital"],"pagination":["973"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11514859"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["22(1)"],"pubmed_abstract":["Background
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICBs) such as anti-PD-1 antibodies, has revolutionised cancer treatment, although response rates vary among patients. Previous studies have demonstrated that caerin 1.1 and 1.9, host-defence peptides from the Australian tree frog, enhance the effectiveness of anti-PD-1 and therapeutic vaccines in a murine TC-1 model by activating tumour-associated macrophages intratumorally.Methods
We employed a murine B16 melanoma model to investigate the therapeutic potential of caerin 1.1 and 1.9 in combination with anti-CD47 and a therapeutic vaccine (triple therapy, TT). Tumour growth of caerin-injected primary tumours and distant metastatic tumours was assessed, and survival analysis conducted. Single-cell RNA"],"journal":["Journal of translational medicine"],"pubmed_title":["Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages."],"pmcid":["PMC11514859"],"funding_grant_id":["2020A1515010855","31971355","2019A008"],"pubmed_authors":["Liu X","Fu Q","Li H","Li J","Chen Z","Ni G","Wang T","Luo Y"],"additional_accession":[]},"is_claimable":false,"name":"Caerin 1.1 and 1.9 peptides halt B16 melanoma metastatic tumours via expanding cDC1 and reprogramming tumour macrophages.","description":"Background
Cancer immunotherapy, particularly immune checkpoint inhibitors (ICBs) such as anti-PD-1 antibodies, has revolutionised cancer treatment, although response rates vary among patients. Previous studies have demonstrated that caerin 1.1 and 1.9, host-defence peptides from the Australian tree frog, enhance the effectiveness of anti-PD-1 and therapeutic vaccines in a murine TC-1 model by activating tumour-associated macrophages intratumorally.Methods
We employed a murine B16 melanoma model to investigate the therapeutic potential of caerin 1.1 and 1.9 in combination with anti-CD47 and a therapeutic vaccine (triple therapy, TT). Tumour growth of caerin-injected primary tumours and distant metastatic tumours was assessed, and survival analysis conducted. Single-cell RNA","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Oct","modification":"2026-07-06T03:11:21.982Z","creation":"2026-07-06T03:08:44.41Z"},"accession":"S-EPMC11514859","cross_references":{"pubmed":["39468595"],"doi":["10.1186/s12967-024-05763-x"]}}